Kaplan-Meier curves for OS risk of AML evolution according to TP53 VAF cutoff point of 20%. (A) TP53-monoallelic patients with a VAF ≥20% (n = 48 [50%]) presented similar OS to TP53-multihit patients (median OS was 51.5 and 56.9 months, respectively; P = .46). TP53-monoallelic patients with a VAF <20% (n = 48 [50%]) presented similar OS to TP53-wt patients (median OS was 91.1 and 77.3 months, respectively; P = .22). (B) TP53-monoallelic patients with a VAF ≥20% (n = 48 [50%]) presented similar risk of AML evolution at 60 months to TP53-multihit patients (32.2% and 40.4%, respectively; P = .17). TP53-monoallelic patients with a VAF <20% (n = 48 [50%]) presented similar risk of AML evolution at 60 months to TP53-wt patients (19.7% and 19.7%, respectively; P = .35).